AzTrials
AzTrials

MastectomyNCT05368519

Brijjit® for Wound Closure in Gender Affirming Mastectomies

A study testing Brijjit® in people with Mastectomy, run by NYU Langone Health at 1 site in United States.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

This study will evaluate the use of Brijjit® for wound closure in individuals undergoing bilateral double incision gender affirming mastectomies with a single surgeon (Rachel Bluebond-Langner, MD). Read more about this study

Who is it for?
Ages 18 to 99 yearsHealthy volunteers can take part
Conditions the study is for
Mastectomy
What is being tested?
Brijjit®
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
1 siteUnited States
Study dates
1 Jun 2022to 19 Apr 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Patient self-identifies as Transgender or Gender Expansive
  • Patient will undergo primary bilateral double incision mastectomy at NYULH
  • All clinical criteria to be eligible for primary mastectomy must be met
  • Ability to care for donor site and adhere to wound therapy (either solo or with care-giver assistance)
  • Willingness to return for scheduled follow-up visits through 1 year post-operatively
  • 18 years of age or older
  • English Speaking

Who cannot join

  • Individuals with previously diagnosed allergies or a history of adverse effects related to adhesives / adhesive tapes
  • Individuals with a history of the following prescription medication use in the last year: Accutane, Systemic glucocorticoids and/or Local glucocorticoids or immunosuppressants (i.e. topical tacrolimus, topical clindamycin etc.) at the intervention site
  • Individuals with a history of significant scarring or adverse scarring (hypertrophic scars or keloid scars)
  • Individuals with pre-existing scars at the GAM wound closure site
  • Individuals with a disorder known to negatively affect wound healing (i.e. autoimmune disease, connective tissue disease)
  • Individuals with malnutrition
Show all 14Show fewer
  • Individuals with a BMI >30 kg/m2
  • Individuals with a history of radiation therapy
  • Active smokers or smokeless nicotine use
  • History of Previous Mastectomy
  • Patient is actively immunosuppressed i.e. AIDS (HIV+ acceptable), or Systemic immunosuppressants
  • Patients unable to attend post-operative follow-ups in person
  • Patients with a considerable history of medical non-compliance
  • Patient will receive GAM not including double incisions (i.e. periareolar)

Trial locations and contacts

1 site in 1 country.

United States1 site
  • NYU Langone Health

    New York, New York, 10016

Other trials in United States

About this study

Official title: A Single-Center Study of Brijjit® - A Force Modulating Tissue Bridge For Skin Closure in Gender-Affirming Mastectomies

This study will evaluate the use of Brijjit® for wound closure in individuals undergoing bilateral double incision gender affirming mastectomies with a single surgeon (Rachel Bluebond-Langner, MD). The study will be a randomized prospective interventional study utilizing internal controls (one side of chest receives intervention, other serves as control). Primary endpoints will include scar appearance/quality and wound complications

Read the detailed description

The hypothesis of this study is that the use of Brijjit® FMTB will result in improved scar outcomes as measured by both patient and treating physician as compared to traditional suture based wound closure methods. As mentioned, at present there is no standard of care for wound closure following double incision GAM, therefore an internal control approach will be taken with patients serving as their own controls. This will be achieved by having one side of the chest receive the of Brijjit® FMTB (intervention) in addition to suture closure of the skin, while the other side will be closed with traditional methods, a combination of sutures and steri-stripsTM (control).

Conditions
Mastectomy
Being tested
Brijjit®

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Brijjit®Device

    Also called Brijjit® BP100-6

    Brijjit® is a non-invasive device which serves as a force modulating tissues bridges (FMTB) to aid in wound healing. This device used in would closure and serves to modify the mechanical forces on a wound which are implicated in adverse outcomes including scar formation and complications like wound dehiscence. Brijjit® is a flexible device which attaches via adhesive to the tissue on either side of the wound, approximates the tissue and off-loads forces.

Study groups in NCT05368519
Study groupRoleWhat they receive
Right chest with Brijjit® FMTBExperimentalPatients will be assigned to have their right chest closure completed via Brijjit® FMTB. While the other chest (not selected for intervention) will be closed via traditional suture-based methods and will serve as an internal control.
Receives: Device: Brijjit®
Left chest with Brijjit® FMTBExperimentalPatients will be assigned to have their left chest closure completed via Brijjit® FMTB. While the other chest (not selected for intervention) will be closed via traditional suture-based methods and will serve as an internal control.
Receives: Device: Brijjit®

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Subjective scar evaluation by patient outcomes using POSAS

    Patient and Observer assessment scale (POSAS) will be used to visually assess their scar appearance and complete the 10-point scale. The patient scale will include questions regarding pain, itch, thickness, color, stiffness, irregularity, and overall opinion. Each item on both scales has a score of 1 to 10. The lowest score is 1 and corresponds to the normal skin situation. The total score of both scales can be calculated simply by adding the scores of each of the six items. The total score will range from 6 to 60.

    Measured: screening/baseline visit

  2. Subjective scar evaluation by patient outcomes using POSAS

    Patient and Observer assessment scale (POSAS) will be used to visually assess their scar appearance and complete the 10-point scale. The patient scale will include questions regarding pain, itch, thickness, color, stiffness, irregularity, and overall opinion. Each item on both scales has a score of 1 to 10. The lowest score is 1 and corresponds to the normal skin situation. The total score of both scales can be calculated simply by adding the scores of each of the six items. The total score will range from 6 to 60.

    Measured: week 2 visit

  3. Subjective scar evaluation by patient outcomes using POSAS

    Patient and Observer assessment scale (POSAS) will be used to visually assess their scar appearance and complete the 10-point scale. The patient scale will include questions regarding pain, itch, thickness, color, stiffness, irregularity, and overall opinion. Each item on both scales has a score of 1 to 10. The lowest score is 1 and corresponds to the normal skin situation. The total score of both scales can be calculated simply by adding the scores of each of the six items. The total score will range from 6 to 60.

    Measured: week 4 visit

  4. Subjective scar evaluation by patient outcomes using POSAS

    Patient and Observer assessment scale (POSAS) will be used to visually assess their scar appearance and complete the 10-point scale. The patient scale will include questions regarding pain, itch, thickness, color, stiffness, irregularity, and overall opinion. Each item on both scales has a score of 1 to 10. The lowest score is 1 and corresponds to the normal skin situation. The total score of both scales can be calculated simply by adding the scores of each of the six items. The total score will range from 6 to 60.

    Measured: week 6 visit

  5. Subjective scar evaluation by patient outcomes using POSAS

    Patient and Observer assessment scale (POSAS) will be used to visually assess their scar appearance and complete the 10-point scale. The patient scale will include questions regarding pain, itch, thickness, color, stiffness, irregularity, and overall opinion. Each item on both scales has a score of 1 to 10. The lowest score is 1 and corresponds to the normal skin situation. The total score of both scales can be calculated simply by adding the scores of each of the six items. The total score will range from 6 to 60.

    Measured: week 8 visit

  6. Subjective scar evaluation by patient outcomes using POSAS

    Patient and Observer assessment scale (POSAS) will be used to visually assess their scar appearance and complete the 10-point scale. The patient scale will include questions regarding pain, itch, thickness, color, stiffness, irregularity, and overall opinion. Each item on both scales has a score of 1 to 10. The lowest score is 1 and corresponds to the normal skin situation. The total score of both scales can be calculated simply by adding the scores of each of the six items. The total score will range from 6 to 60.

    Measured: 3-month post-surgery visit

  7. Subjective scar evaluation by patient outcomes using POSAS

    Patient and Observer assessment scale (POSAS) will be used to visually assess their scar appearance and complete the 10-point scale. The patient scale will include questions regarding pain, itch, thickness, color, stiffness, irregularity, and overall opinion. Each item on both scales has a score of 1 to 10. The lowest score is 1 and corresponds to the normal skin situation. The total score of both scales can be calculated simply by adding the scores of each of the six items. The total score will range from 6 to 60.

    Measured: 6-months post-surgery visit

  8. Subjective scar evaluation by patient outcomes using POSAS

    Patient and Observer assessment scale (POSAS) will be used to visually assess their scar appearance and complete the 10-point scale. The patient scale will include questions regarding pain, itch, thickness, color, stiffness, irregularity, and overall opinion. Each item on both scales has a score of 1 to 10. The lowest score is 1 and corresponds to the normal skin situation. The total score of both scales can be calculated simply by adding the scores of each of the six items. The total score will range from 6 to 60.

    Measured: 12-months post-surgery visit

  9. Subjective scar evaluation by surgeon outcomes using POSAS

    Clinician will visually assess the scar appearance during the visit and complete the 10-point scale. The observer scale will include items with subcategories related to vascularity, pigmentation, relief/texture, thickness, pliability, surface area and overall opinion.Scores are tabulated out of 70. Each item on both scales has a score of 1 to 10. The lowest score is 1 and corresponds to the normal skin situation. The total score of both scales can be calculated simply by adding the scores of each of the six items. The total score will range from 6 to 60.

    Measured: screening/baseline visit

  10. Subjective scar evaluation by surgeon outcomes using POSAS

    Clinician will visually assess the scar appearance during the visit and complete the 10-point scale. The observer scale will include items with subcategories related to vascularity, pigmentation, relief/texture, thickness, pliability, surface area and overall opinion.Scores are tabulated out of 70. Each item on both scales has a score of 1 to 10. The lowest score is 1 and corresponds to the normal skin situation. The total score of both scales can be calculated simply by adding the scores of each of the six items. The total score will range from 6 to 60.

    Measured: week 2 visit

  11. Subjective scar evaluation by surgeon outcomes using POSAS

    Clinician will visually assess the scar appearance during the visit and complete the 10-point scale. The observer scale will include items with subcategories related to vascularity, pigmentation, relief/texture, thickness, pliability, surface area and overall opinion.Scores are tabulated out of 70. Each item on both scales has a score of 1 to 10. The lowest score is 1 and corresponds to the normal skin situation. The total score of both scales can be calculated simply by adding the scores of each of the six items. The total score will range from 6 to 60.

    Measured: week 4 visit

  12. Subjective scar evaluation by surgeon outcomes using POSAS

    Clinician will visually assess the scar appearance during the visit and complete the 10-point scale. The observer scale will include items with subcategories related to vascularity, pigmentation, relief/texture, thickness, pliability, surface area and overall opinion.Scores are tabulated out of 70. Each item on both scales has a score of 1 to 10. The lowest score is 1 and corresponds to the normal skin situation. The total score of both scales can be calculated simply by adding the scores of each of the six items. The total score will range from 6 to 60.

    Measured: week 6 visit

  13. Subjective scar evaluation by surgeon outcomes using POSAS

    Clinician will visually assess the scar appearance during the visit and complete the 10-point scale. The observer scale will include items with subcategories related to vascularity, pigmentation, relief/texture, thickness, pliability, surface area and overall opinion.Scores are tabulated out of 70. Each item on both scales has a score of 1 to 10. The lowest score is 1 and corresponds to the normal skin situation. The total score of both scales can be calculated simply by adding the scores of each of the six items. The total score will range from 6 to 60.

    Measured: week 8 visit

  14. Subjective scar evaluation by surgeon outcomes using POSAS

    Clinician will visually assess the scar appearance during the visit and complete the 10-point scale. The observer scale will include items with subcategories related to vascularity, pigmentation, relief/texture, thickness, pliability, surface area and overall opinion.Scores are tabulated out of 70. Each item on both scales has a score of 1 to 10. The lowest score is 1 and corresponds to the normal skin situation. The total score of both scales can be calculated simply by adding the scores of each of the six items. The total score will range from 6 to 60.

    Measured: 3-month post-surgery visit

  15. Subjective scar evaluation by surgeon outcomes using POSAS

    Clinician will visually assess the scar appearance during the visit and complete the 10-point scale. The observer scale will include items with subcategories related to vascularity, pigmentation, relief/texture, thickness, pliability, surface area and overall opinion.Scores are tabulated out of 70. Each item on both scales has a score of 1 to 10. The lowest score is 1 and corresponds to the normal skin situation. The total score of both scales can be calculated simply by adding the scores of each of the six items. The total score will range from 6 to 60.

    Measured: 6-months post-surgery visit

  16. Subjective scar evaluation by surgeon outcomes using POSAS

    Clinician will visually assess the scar appearance during the visit and complete the 10-point scale. The observer scale will include items with subcategories related to vascularity, pigmentation, relief/texture, thickness, pliability, surface area and overall opinion.Scores are tabulated out of 70. Each item on both scales has a score of 1 to 10. The lowest score is 1 and corresponds to the normal skin situation. The total score of both scales can be calculated simply by adding the scores of each of the six items. The total score will range from 6 to 60.

    Measured: 12-months post-surgery visit

  17. Photographic assessment for objective scar evaluation

    Standard and close-up photography (part of standard of care) will be utilized for evaluation of the appearance surgical scars. These photographs will be taken utilizing the Nikon D7200 at screening/baseline, week 2, week 4, week 6, week 8, 3-month post-surgery, 6-months post-surgery and 12-months post-surgery. There will be no statistical analyses employed on the photographs

    Measured: screening/baseline visir

  18. Photographic assessment for objective scar evaluation

    Standard and close-up photography (part of standard of care) will be utilized for evaluation of the appearance surgical scars. These photographs will be taken utilizing the Nikon D7200 at screening/baseline, week 2, week 4, week 6, week 8, 3-month post-surgery, 6-months post-surgery and 12-months post-surgery. There will be no statistical analyses employed on the photographs

    Measured: week 2 visit

  19. Photographic assessment for objective scar evaluation

    Standard and close-up photography (part of standard of care) will be utilized for evaluation of the appearance surgical scars. These photographs will be taken utilizing the Nikon D7200 at screening/baseline, week 2, week 4, week 6, week 8, 3-month post-surgery, 6-months post-surgery and 12-months post-surgery. There will be no statistical analyses employed on the photographs

    Measured: week 4 visit

  20. Photographic assessment for objective scar evaluation

    Standard and close-up photography (part of standard of care) will be utilized for evaluation of the appearance surgical scars. These photographs will be taken utilizing the Nikon D7200 at screening/baseline, week 2, week 4, week 6, week 8, 3-month post-surgery, 6-months post-surgery and 12-months post-surgery. There will be no statistical analyses employed on the photographs

    Measured: week 6 visit

  21. Photographic assessment for objective scar evaluation

    Standard and close-up photography (part of standard of care) will be utilized for evaluation of the appearance surgical scars. These photographs will be taken utilizing the Nikon D7200 at screening/baseline, week 2, week 4, week 6, week 8, 3-month post-surgery, 6-months post-surgery and 12-months post-surgery. There will be no statistical analyses employed on the photographs

    Measured: week 8 visit

  22. Photographic assessment for objective scar evaluation

    Standard and close-up photography (part of standard of care) will be utilized for evaluation of the appearance surgical scars. These photographs will be taken utilizing the Nikon D7200 at screening/baseline, week 2, week 4, week 6, week 8, 3-month post-surgery, 6-months post-surgery and 12-months post-surgery. There will be no statistical analyses employed on the photographs

    Measured: 3-month post-surgery visit

  23. Photographic assessment for objective scar evaluation

    Standard and close-up photography (part of standard of care) will be utilized for evaluation of the appearance surgical scars. These photographs will be taken utilizing the Nikon D7200 at screening/baseline, week 2, week 4, week 6, week 8, 3-month post-surgery, 6-months post-surgery and 12-months post-surgery. There will be no statistical analyses employed on the photographs

    Measured: 6-months post-surgery visit

  24. Photographic assessment for objective scar evaluation

    Standard and close-up photography (part of standard of care) will be utilized for evaluation of the appearance surgical scars. These photographs will be taken utilizing the Nikon D7200 at screening/baseline, week 2, week 4, week 6, week 8, 3-month post-surgery, 6-months post-surgery and 12-months post-surgery. There will be no statistical analyses employed on the photographs

    Measured: 12-months post-surgery visit

  25. Colorimetry of Scar

    The Pantone SkinTone Guide is a handheld tool consisting of 110 color swatches that realistically mimic human skin tones, with stepwise variations in lightness and undertone. The guide was specifically formulated to be the closest physical representation of skin colors and is the only internationally available color standard to accurately match skin tones. Each SkinTone number is comprised of a four-digit alphanumeric number; the first two numbers reflect the hue or undertone of the skin while the second two represent the tone or lightness and darkness of the skin. This tool will be utilized to establish a clinically acceptable objective assessment for assessing the coloring of patients' scars.

    Measured: screening/baseline visit

  26. Colorimetry of Scar

    The Pantone SkinTone Guide is a handheld tool consisting of 110 color swatches that realistically mimic human skin tones, with stepwise variations in lightness and undertone. The guide was specifically formulated to be the closest physical representation of skin colors and is the only internationally available color standard to accurately match skin tones. Each SkinTone number is comprised of a four-digit alphanumeric number; the first two numbers reflect the hue or undertone of the skin while the second two represent the tone or lightness and darkness of the skin. This tool will be utilized to establish a clinically acceptable objective assessment for assessing the coloring of patients' scars.

    Measured: week 2 visit

  27. Colorimetry of Scar

    The Pantone SkinTone Guide is a handheld tool consisting of 110 color swatches that realistically mimic human skin tones, with stepwise variations in lightness and undertone. The guide was specifically formulated to be the closest physical representation of skin colors and is the only internationally available color standard to accurately match skin tones. Each SkinTone number is comprised of a four-digit alphanumeric number; the first two numbers reflect the hue or undertone of the skin while the second two represent the tone or lightness and darkness of the skin. This tool will be utilized to establish a clinically acceptable objective assessment for assessing the coloring of patients' scars.

    Measured: week 4 visit

  28. Colorimetry of Scar

    The Pantone SkinTone Guide is a handheld tool consisting of 110 color swatches that realistically mimic human skin tones, with stepwise variations in lightness and undertone. The guide was specifically formulated to be the closest physical representation of skin colors and is the only internationally available color standard to accurately match skin tones. Each SkinTone number is comprised of a four-digit alphanumeric number; the first two numbers reflect the hue or undertone of the skin while the second two represent the tone or lightness and darkness of the skin. This tool will be utilized to establish a clinically acceptable objective assessment for assessing the coloring of patients' scars.

    Measured: week 6 visit

  29. Colorimetry of Scar

    The Pantone SkinTone Guide is a handheld tool consisting of 110 color swatches that realistically mimic human skin tones, with stepwise variations in lightness and undertone. The guide was specifically formulated to be the closest physical representation of skin colors and is the only internationally available color standard to accurately match skin tones. Each SkinTone number is comprised of a four-digit alphanumeric number; the first two numbers reflect the hue or undertone of the skin while the second two represent the tone or lightness and darkness of the skin. This tool will be utilized to establish a clinically acceptable objective assessment for assessing the coloring of patients' scars.

    Measured: week 8 visit

  30. Colorimetry of Scar

    The Pantone SkinTone Guide is a handheld tool consisting of 110 color swatches that realistically mimic human skin tones, with stepwise variations in lightness and undertone. The guide was specifically formulated to be the closest physical representation of skin colors and is the only internationally available color standard to accurately match skin tones. Each SkinTone number is comprised of a four-digit alphanumeric number; the first two numbers reflect the hue or undertone of the skin while the second two represent the tone or lightness and darkness of the skin. This tool will be utilized to establish a clinically acceptable objective assessment for assessing the coloring of patients' scars.

    Measured: 3-month post-surgery visit

  31. Colorimetry of Scar

    The Pantone SkinTone Guide is a handheld tool consisting of 110 color swatches that realistically mimic human skin tones, with stepwise variations in lightness and undertone. The guide was specifically formulated to be the closest physical representation of skin colors and is the only internationally available color standard to accurately match skin tones. Each SkinTone number is comprised of a four-digit alphanumeric number; the first two numbers reflect the hue or undertone of the skin while the second two represent the tone or lightness and darkness of the skin. This tool will be utilized to establish a clinically acceptable objective assessment for assessing the coloring of patients' scars.

    Measured: 6-months post-surgery visit

  32. Colorimetry of Scar

    The Pantone SkinTone Guide is a handheld tool consisting of 110 color swatches that realistically mimic human skin tones, with stepwise variations in lightness and undertone. The guide was specifically formulated to be the closest physical representation of skin colors and is the only internationally available color standard to accurately match skin tones. Each SkinTone number is comprised of a four-digit alphanumeric number; the first two numbers reflect the hue or undertone of the skin while the second two represent the tone or lightness and darkness of the skin. This tool will be utilized to establish a clinically acceptable objective assessment for assessing the coloring of patients' scars.

    Measured: 12-months post-surgery visit

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 May 2022
  2. Study start1 Jun 2022 (estimated)
  3. Primary completion19 Apr 2024 (estimated)
  4. Study completion19 Apr 2024 (estimated)

Why it stopped: Patients were not interested in participating in the study

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05368519
Sponsor's protocol ID
22-00304
Status last verified
Aug 2022
First submitted
3 May 2022
Last updated
9 Aug 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
Yes: Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

Questions about this trial

What is this clinical trial studying?

A study testing Brijjit® in people with Mastectomy, run by NYU Langone Health at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 9 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Subjective scar evaluation by patient outcomes using POSAS (time frame: screening/baseline visit). The study lists 32 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Aug 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in